Abstract
In a recent study, the authors suggested that tachycardia, dry mouth, and sweating continued to burden patients with panic disorder with agoraphobia who have shown marked and stable response to 6 months of imipramine treatment at the fixed, weight-adjusted dose of 2.25 mg/kg/day. Although sexual dysfunction and weight gain were not a significant burden in that study, they are important problems in long-term treatment with antidepressant drugs. In the present study, in the context of a randomized, double-blind, placebo-controlled, 1-year discontinuation and maintenance study of 53 patients with panic disorder with agoraphobia who respond to imipramine, the authors examine the extent and the specificity of these five side effects of imipramine maintenance using data at pretreatment, at the end of 24 weeks of open imipramine treatment (or month 0 of randomization), and at months 2, 4, 6, 8, 10, and 12 of randomized treatment. Hierarchical linear modeling and repeated measures of analyses of variance in subsamples of completers confirmed that dry mouth, sweating, and increased heart rate constitute a significant and specific enduring burden of imipramine maintenance treatment. The data also revealed that weight gain is a significan...Continue Reading
References
Sep 1, 1992·Journal of Affective Disorders·E FrankV J Grochocinski
Nov 1, 1990·Journal of Affective Disorders·E FrankJ A Levenson
Jun 1, 1986·Journal of Clinical Psychopharmacology·W M HarrisonF M Quitkin
Oct 1, 1984·Journal of Affective Disorders·G H BerkenW C Stern
Feb 1, 1997·Acta Psychiatrica Scandinavica·Y LecrubierR Judge
Feb 1, 1997·Acta Psychiatrica Scandinavica·Y Lecrubier, R Judge
Jun 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·A G WadeT Pedersen
Dec 16, 1997·The American Journal of Psychiatry·L A PiazzaD Adler
Jun 5, 1998·Biological Psychiatry·M R MavissakalianC Sloan
Jun 17, 1998·Biological Psychiatry·L A LabbateG W Arana
Nov 18, 1998·The Journal of Clinical Psychiatry·U M LepolaH J Lehto
Sep 23, 2000·Journal of Clinical Psychopharmacology·M R Mavissakalian, J M Perel
Nov 14, 2000·Archives of General Psychiatry·C M Meston, P F Frohlich
Jul 30, 2003·Archives of General Psychiatry·M R Mavissakalian, J M Perel
Jan 1, 1959·The British Journal of Medical Psychology·M HAMILTON
Citations
Dec 5, 2002·Pharmacoepidemiology and Drug Safety
May 31, 2011·The Urologic Clinics of North America·Michael A Perelman
Feb 24, 2011·Expert Opinion on Pharmacotherapy·Rafael C FreireAntonio E Nardi
Apr 12, 2015·Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology·Ardita AlikoArjan Vissink
Sep 26, 2012·Expert Review of Neurotherapeutics·Lindsey B DeBoerJasper A J Smits
Feb 21, 2013·Journal of Clinical Psychopharmacology·Rajnish Mago
Sep 17, 2003·Oral Diseases·C Scully
Sep 8, 2017·Depression and Anxiety·Chad BeyerMichael H Bloch
Sep 10, 2020·Brain Research Bulletin·Ying-Jie WangBo Jiang